Cancer immunotherapy, specifically immune checkpoint blockade therapy, has been found to be effective in the treatment of metastatic cancers. However, many patients do not show marked clinical response. Consequently, elucidating immune system-related pre-treatment biomarkers that are predictive with respect to sustained clinical response is a major research priority. Another research priority is evaluating changes in immune signaling networks before and after treatment in responders and non-responders. High-dimensional flow cytometry data (FACS, Fluorescence-activated cell sorting) characterizing...